Plasma VAP-1/SSAO Activity Predicts Intracranial Hemorrhages and Adverse Neurological Outcome After Tissue Plasminogen Activator Treatment in Stroke
Vascular adhesion protein-1 (VAP-1) is a cell surface and circulating enzyme involved in recruitment of lymphocytes and neutrophils through its semicarbazide-sensitive amine oxidase (SSAO) activity. We aimed to study plasma VAP-1/SSAO activity in relation to the risk for intracranial bleeding compli...
Gespeichert in:
| Veröffentlicht in: | Stroke (1970) 2010-07, Vol.41 (7), p.1528-1535 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1535 |
|---|---|
| container_issue | 7 |
| container_start_page | 1528 |
| container_title | Stroke (1970) |
| container_volume | 41 |
| creator | HERNANDEZ-GUILLAMON, Mar GARCIA-BONILLA, Lidia QUINTANA, Manolo MOLINA, Carlos A ALVAREZ-SABIN, José ROSELL, Anna UNZETA, Mercedes MONTANER, Joan SOLE, Montse SOSTI, Victoria PARES, Mireia CAMPOS, Mireia ORTEGA-AZNAR, Arantxa DOMINGUEZ, Carmen RUBIERA, Marta RIBO, Marc |
| description | Vascular adhesion protein-1 (VAP-1) is a cell surface and circulating enzyme involved in recruitment of lymphocytes and neutrophils through its semicarbazide-sensitive amine oxidase (SSAO) activity. We aimed to study plasma VAP-1/SSAO activity in relation to the risk for intracranial bleeding complications in patients with stroke treated with tissue plasminogen activator (tPA), the greatest safety concern with this treatment.
In 141 patients with ischemic stroke, we measured VAP-1/SSAO activity in plasma taken before tPA administration. Hemorrhagic events were classified according to brain CT criteria and functional outcomes evaluated using the National Institutes of Health Stroke Scale. We also assessed the potential therapeutic effect of blocking VAP-1/SSAO activity in a rat embolic stroke model treated with tPA.
We saw significantly higher levels of plasma VAP-1/SSAO activity in patients who subsequently experienced hemorrhagic transformation. Elevated plasma VAP-1/SSAO activity also predicted worse neurological outcome in these patients. In the rat model, we confirmed that use of the inhibitor semicarbazide prevented adverse effects caused by delayed tPA administration, leading to a smaller infarct volume.
Our data demonstrate that baseline VAP-1/SSAO activity predicts parenchymal hemorrhage after tPA, suggesting the safety of thrombolytic agents could be improved by considering VAP-1/SSAO activity. Furthermore, anti-VAP-1/SSAO drugs given with tPA may prevent neurological worsening in patients with ischemic stroke. |
| doi_str_mv | 10.1161/STROKEAHA.110.584623 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733477753</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733477753</sourcerecordid><originalsourceid>FETCH-LOGICAL-c382t-592c561cad651f39ea8666d06c89875b0c81b9acf31675e5be3d95daab425bb73</originalsourceid><addsrcrecordid>eNpFkd1u1DAQhS1ERZfCGyDkG9SrtP6JHfsyqlq2asWu2IXbyHEmi9skbm2nUt-DB8Z0l3I1M5pv5kjnIPSJkjNKJT3fbL-vbi7rZZ1HciZUKRl_gxZUsLLIvXqLFoRwXbBS62P0PsY7QgjjSrxDx4wIrqQuF-j3ejBxNPhnvS7yz029wrVN7smlZ7wO0DmbIr6eUjA2mMmZAS9h9CH8MjuI2EwdrrsnCBHwN5iDH_zO2Qyt5mT9CLjuEwS8dTHOgF-k3OR3MO1FTPJ5GcCkEaaE3YQ3Kfh7-ICOejNE-HioJ-jH1eX2Ylncrr5eX9S3heWKpUJoZoWk1nRS0J5rMEpK2RFplVaVaIlVtNXG9pzKSoBogXdadMa0JRNtW_ETdLr_-xD84wwxNaOLFobBTODn2FScl1VVCZ7Jck_a4GMM0DcPwY0mPDeUNH_jaF7jyCNp9nHks88HgbkdoXs9-ud_Br4cABOzb3322Lr4n2NaC60Y_wPOPZXW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733477753</pqid></control><display><type>article</type><title>Plasma VAP-1/SSAO Activity Predicts Intracranial Hemorrhages and Adverse Neurological Outcome After Tissue Plasminogen Activator Treatment in Stroke</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>HERNANDEZ-GUILLAMON, Mar ; GARCIA-BONILLA, Lidia ; QUINTANA, Manolo ; MOLINA, Carlos A ; ALVAREZ-SABIN, José ; ROSELL, Anna ; UNZETA, Mercedes ; MONTANER, Joan ; SOLE, Montse ; SOSTI, Victoria ; PARES, Mireia ; CAMPOS, Mireia ; ORTEGA-AZNAR, Arantxa ; DOMINGUEZ, Carmen ; RUBIERA, Marta ; RIBO, Marc</creator><creatorcontrib>HERNANDEZ-GUILLAMON, Mar ; GARCIA-BONILLA, Lidia ; QUINTANA, Manolo ; MOLINA, Carlos A ; ALVAREZ-SABIN, José ; ROSELL, Anna ; UNZETA, Mercedes ; MONTANER, Joan ; SOLE, Montse ; SOSTI, Victoria ; PARES, Mireia ; CAMPOS, Mireia ; ORTEGA-AZNAR, Arantxa ; DOMINGUEZ, Carmen ; RUBIERA, Marta ; RIBO, Marc</creatorcontrib><description>Vascular adhesion protein-1 (VAP-1) is a cell surface and circulating enzyme involved in recruitment of lymphocytes and neutrophils through its semicarbazide-sensitive amine oxidase (SSAO) activity. We aimed to study plasma VAP-1/SSAO activity in relation to the risk for intracranial bleeding complications in patients with stroke treated with tissue plasminogen activator (tPA), the greatest safety concern with this treatment.
In 141 patients with ischemic stroke, we measured VAP-1/SSAO activity in plasma taken before tPA administration. Hemorrhagic events were classified according to brain CT criteria and functional outcomes evaluated using the National Institutes of Health Stroke Scale. We also assessed the potential therapeutic effect of blocking VAP-1/SSAO activity in a rat embolic stroke model treated with tPA.
We saw significantly higher levels of plasma VAP-1/SSAO activity in patients who subsequently experienced hemorrhagic transformation. Elevated plasma VAP-1/SSAO activity also predicted worse neurological outcome in these patients. In the rat model, we confirmed that use of the inhibitor semicarbazide prevented adverse effects caused by delayed tPA administration, leading to a smaller infarct volume.
Our data demonstrate that baseline VAP-1/SSAO activity predicts parenchymal hemorrhage after tPA, suggesting the safety of thrombolytic agents could be improved by considering VAP-1/SSAO activity. Furthermore, anti-VAP-1/SSAO drugs given with tPA may prevent neurological worsening in patients with ischemic stroke.</description><identifier>ISSN: 0039-2499</identifier><identifier>EISSN: 1524-4628</identifier><identifier>DOI: 10.1161/STROKEAHA.110.584623</identifier><identifier>PMID: 20538694</identifier><identifier>CODEN: SJCCA7</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Aged ; Aged, 80 and over ; Amine Oxidase (Copper-Containing) - blood ; Animals ; Biological and medical sciences ; Biomarkers - blood ; Blood. Blood coagulation. Reticuloendothelial system ; Cell Adhesion Molecules - blood ; Enzyme Activation - drug effects ; Enzyme Activation - physiology ; Female ; Humans ; Intracranial Hemorrhages - drug therapy ; Intracranial Hemorrhages - enzymology ; Intracranial Hemorrhages - etiology ; Male ; Medical sciences ; Middle Aged ; Nervous System Diseases - drug therapy ; Nervous System Diseases - enzymology ; Nervous System Diseases - etiology ; Neurology ; Pharmacology. Drug treatments ; Predictive Value of Tests ; Prospective Studies ; Rats ; Rats, Sprague-Dawley ; Stroke - complications ; Stroke - drug therapy ; Stroke - enzymology ; Tissue Plasminogen Activator - adverse effects ; Treatment Outcome ; Vascular diseases and vascular malformations of the nervous system</subject><ispartof>Stroke (1970), 2010-07, Vol.41 (7), p.1528-1535</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c382t-592c561cad651f39ea8666d06c89875b0c81b9acf31675e5be3d95daab425bb73</citedby><cites>FETCH-LOGICAL-c382t-592c561cad651f39ea8666d06c89875b0c81b9acf31675e5be3d95daab425bb73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3687,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22995982$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20538694$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HERNANDEZ-GUILLAMON, Mar</creatorcontrib><creatorcontrib>GARCIA-BONILLA, Lidia</creatorcontrib><creatorcontrib>QUINTANA, Manolo</creatorcontrib><creatorcontrib>MOLINA, Carlos A</creatorcontrib><creatorcontrib>ALVAREZ-SABIN, José</creatorcontrib><creatorcontrib>ROSELL, Anna</creatorcontrib><creatorcontrib>UNZETA, Mercedes</creatorcontrib><creatorcontrib>MONTANER, Joan</creatorcontrib><creatorcontrib>SOLE, Montse</creatorcontrib><creatorcontrib>SOSTI, Victoria</creatorcontrib><creatorcontrib>PARES, Mireia</creatorcontrib><creatorcontrib>CAMPOS, Mireia</creatorcontrib><creatorcontrib>ORTEGA-AZNAR, Arantxa</creatorcontrib><creatorcontrib>DOMINGUEZ, Carmen</creatorcontrib><creatorcontrib>RUBIERA, Marta</creatorcontrib><creatorcontrib>RIBO, Marc</creatorcontrib><title>Plasma VAP-1/SSAO Activity Predicts Intracranial Hemorrhages and Adverse Neurological Outcome After Tissue Plasminogen Activator Treatment in Stroke</title><title>Stroke (1970)</title><addtitle>Stroke</addtitle><description>Vascular adhesion protein-1 (VAP-1) is a cell surface and circulating enzyme involved in recruitment of lymphocytes and neutrophils through its semicarbazide-sensitive amine oxidase (SSAO) activity. We aimed to study plasma VAP-1/SSAO activity in relation to the risk for intracranial bleeding complications in patients with stroke treated with tissue plasminogen activator (tPA), the greatest safety concern with this treatment.
In 141 patients with ischemic stroke, we measured VAP-1/SSAO activity in plasma taken before tPA administration. Hemorrhagic events were classified according to brain CT criteria and functional outcomes evaluated using the National Institutes of Health Stroke Scale. We also assessed the potential therapeutic effect of blocking VAP-1/SSAO activity in a rat embolic stroke model treated with tPA.
We saw significantly higher levels of plasma VAP-1/SSAO activity in patients who subsequently experienced hemorrhagic transformation. Elevated plasma VAP-1/SSAO activity also predicted worse neurological outcome in these patients. In the rat model, we confirmed that use of the inhibitor semicarbazide prevented adverse effects caused by delayed tPA administration, leading to a smaller infarct volume.
Our data demonstrate that baseline VAP-1/SSAO activity predicts parenchymal hemorrhage after tPA, suggesting the safety of thrombolytic agents could be improved by considering VAP-1/SSAO activity. Furthermore, anti-VAP-1/SSAO drugs given with tPA may prevent neurological worsening in patients with ischemic stroke.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Amine Oxidase (Copper-Containing) - blood</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Cell Adhesion Molecules - blood</subject><subject>Enzyme Activation - drug effects</subject><subject>Enzyme Activation - physiology</subject><subject>Female</subject><subject>Humans</subject><subject>Intracranial Hemorrhages - drug therapy</subject><subject>Intracranial Hemorrhages - enzymology</subject><subject>Intracranial Hemorrhages - etiology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nervous System Diseases - drug therapy</subject><subject>Nervous System Diseases - enzymology</subject><subject>Nervous System Diseases - etiology</subject><subject>Neurology</subject><subject>Pharmacology. Drug treatments</subject><subject>Predictive Value of Tests</subject><subject>Prospective Studies</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Stroke - complications</subject><subject>Stroke - drug therapy</subject><subject>Stroke - enzymology</subject><subject>Tissue Plasminogen Activator - adverse effects</subject><subject>Treatment Outcome</subject><subject>Vascular diseases and vascular malformations of the nervous system</subject><issn>0039-2499</issn><issn>1524-4628</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkd1u1DAQhS1ERZfCGyDkG9SrtP6JHfsyqlq2asWu2IXbyHEmi9skbm2nUt-DB8Z0l3I1M5pv5kjnIPSJkjNKJT3fbL-vbi7rZZ1HciZUKRl_gxZUsLLIvXqLFoRwXbBS62P0PsY7QgjjSrxDx4wIrqQuF-j3ejBxNPhnvS7yz029wrVN7smlZ7wO0DmbIr6eUjA2mMmZAS9h9CH8MjuI2EwdrrsnCBHwN5iDH_zO2Qyt5mT9CLjuEwS8dTHOgF-k3OR3MO1FTPJ5GcCkEaaE3YQ3Kfh7-ICOejNE-HioJ-jH1eX2Ylncrr5eX9S3heWKpUJoZoWk1nRS0J5rMEpK2RFplVaVaIlVtNXG9pzKSoBogXdadMa0JRNtW_ETdLr_-xD84wwxNaOLFobBTODn2FScl1VVCZ7Jck_a4GMM0DcPwY0mPDeUNH_jaF7jyCNp9nHks88HgbkdoXs9-ud_Br4cABOzb3322Lr4n2NaC60Y_wPOPZXW</recordid><startdate>20100701</startdate><enddate>20100701</enddate><creator>HERNANDEZ-GUILLAMON, Mar</creator><creator>GARCIA-BONILLA, Lidia</creator><creator>QUINTANA, Manolo</creator><creator>MOLINA, Carlos A</creator><creator>ALVAREZ-SABIN, José</creator><creator>ROSELL, Anna</creator><creator>UNZETA, Mercedes</creator><creator>MONTANER, Joan</creator><creator>SOLE, Montse</creator><creator>SOSTI, Victoria</creator><creator>PARES, Mireia</creator><creator>CAMPOS, Mireia</creator><creator>ORTEGA-AZNAR, Arantxa</creator><creator>DOMINGUEZ, Carmen</creator><creator>RUBIERA, Marta</creator><creator>RIBO, Marc</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100701</creationdate><title>Plasma VAP-1/SSAO Activity Predicts Intracranial Hemorrhages and Adverse Neurological Outcome After Tissue Plasminogen Activator Treatment in Stroke</title><author>HERNANDEZ-GUILLAMON, Mar ; GARCIA-BONILLA, Lidia ; QUINTANA, Manolo ; MOLINA, Carlos A ; ALVAREZ-SABIN, José ; ROSELL, Anna ; UNZETA, Mercedes ; MONTANER, Joan ; SOLE, Montse ; SOSTI, Victoria ; PARES, Mireia ; CAMPOS, Mireia ; ORTEGA-AZNAR, Arantxa ; DOMINGUEZ, Carmen ; RUBIERA, Marta ; RIBO, Marc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c382t-592c561cad651f39ea8666d06c89875b0c81b9acf31675e5be3d95daab425bb73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Amine Oxidase (Copper-Containing) - blood</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Cell Adhesion Molecules - blood</topic><topic>Enzyme Activation - drug effects</topic><topic>Enzyme Activation - physiology</topic><topic>Female</topic><topic>Humans</topic><topic>Intracranial Hemorrhages - drug therapy</topic><topic>Intracranial Hemorrhages - enzymology</topic><topic>Intracranial Hemorrhages - etiology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nervous System Diseases - drug therapy</topic><topic>Nervous System Diseases - enzymology</topic><topic>Nervous System Diseases - etiology</topic><topic>Neurology</topic><topic>Pharmacology. Drug treatments</topic><topic>Predictive Value of Tests</topic><topic>Prospective Studies</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Stroke - complications</topic><topic>Stroke - drug therapy</topic><topic>Stroke - enzymology</topic><topic>Tissue Plasminogen Activator - adverse effects</topic><topic>Treatment Outcome</topic><topic>Vascular diseases and vascular malformations of the nervous system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HERNANDEZ-GUILLAMON, Mar</creatorcontrib><creatorcontrib>GARCIA-BONILLA, Lidia</creatorcontrib><creatorcontrib>QUINTANA, Manolo</creatorcontrib><creatorcontrib>MOLINA, Carlos A</creatorcontrib><creatorcontrib>ALVAREZ-SABIN, José</creatorcontrib><creatorcontrib>ROSELL, Anna</creatorcontrib><creatorcontrib>UNZETA, Mercedes</creatorcontrib><creatorcontrib>MONTANER, Joan</creatorcontrib><creatorcontrib>SOLE, Montse</creatorcontrib><creatorcontrib>SOSTI, Victoria</creatorcontrib><creatorcontrib>PARES, Mireia</creatorcontrib><creatorcontrib>CAMPOS, Mireia</creatorcontrib><creatorcontrib>ORTEGA-AZNAR, Arantxa</creatorcontrib><creatorcontrib>DOMINGUEZ, Carmen</creatorcontrib><creatorcontrib>RUBIERA, Marta</creatorcontrib><creatorcontrib>RIBO, Marc</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Stroke (1970)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HERNANDEZ-GUILLAMON, Mar</au><au>GARCIA-BONILLA, Lidia</au><au>QUINTANA, Manolo</au><au>MOLINA, Carlos A</au><au>ALVAREZ-SABIN, José</au><au>ROSELL, Anna</au><au>UNZETA, Mercedes</au><au>MONTANER, Joan</au><au>SOLE, Montse</au><au>SOSTI, Victoria</au><au>PARES, Mireia</au><au>CAMPOS, Mireia</au><au>ORTEGA-AZNAR, Arantxa</au><au>DOMINGUEZ, Carmen</au><au>RUBIERA, Marta</au><au>RIBO, Marc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma VAP-1/SSAO Activity Predicts Intracranial Hemorrhages and Adverse Neurological Outcome After Tissue Plasminogen Activator Treatment in Stroke</atitle><jtitle>Stroke (1970)</jtitle><addtitle>Stroke</addtitle><date>2010-07-01</date><risdate>2010</risdate><volume>41</volume><issue>7</issue><spage>1528</spage><epage>1535</epage><pages>1528-1535</pages><issn>0039-2499</issn><eissn>1524-4628</eissn><coden>SJCCA7</coden><abstract>Vascular adhesion protein-1 (VAP-1) is a cell surface and circulating enzyme involved in recruitment of lymphocytes and neutrophils through its semicarbazide-sensitive amine oxidase (SSAO) activity. We aimed to study plasma VAP-1/SSAO activity in relation to the risk for intracranial bleeding complications in patients with stroke treated with tissue plasminogen activator (tPA), the greatest safety concern with this treatment.
In 141 patients with ischemic stroke, we measured VAP-1/SSAO activity in plasma taken before tPA administration. Hemorrhagic events were classified according to brain CT criteria and functional outcomes evaluated using the National Institutes of Health Stroke Scale. We also assessed the potential therapeutic effect of blocking VAP-1/SSAO activity in a rat embolic stroke model treated with tPA.
We saw significantly higher levels of plasma VAP-1/SSAO activity in patients who subsequently experienced hemorrhagic transformation. Elevated plasma VAP-1/SSAO activity also predicted worse neurological outcome in these patients. In the rat model, we confirmed that use of the inhibitor semicarbazide prevented adverse effects caused by delayed tPA administration, leading to a smaller infarct volume.
Our data demonstrate that baseline VAP-1/SSAO activity predicts parenchymal hemorrhage after tPA, suggesting the safety of thrombolytic agents could be improved by considering VAP-1/SSAO activity. Furthermore, anti-VAP-1/SSAO drugs given with tPA may prevent neurological worsening in patients with ischemic stroke.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>20538694</pmid><doi>10.1161/STROKEAHA.110.584623</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0039-2499 |
| ispartof | Stroke (1970), 2010-07, Vol.41 (7), p.1528-1535 |
| issn | 0039-2499 1524-4628 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733477753 |
| source | MEDLINE; American Heart Association Journals; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Aged Aged, 80 and over Amine Oxidase (Copper-Containing) - blood Animals Biological and medical sciences Biomarkers - blood Blood. Blood coagulation. Reticuloendothelial system Cell Adhesion Molecules - blood Enzyme Activation - drug effects Enzyme Activation - physiology Female Humans Intracranial Hemorrhages - drug therapy Intracranial Hemorrhages - enzymology Intracranial Hemorrhages - etiology Male Medical sciences Middle Aged Nervous System Diseases - drug therapy Nervous System Diseases - enzymology Nervous System Diseases - etiology Neurology Pharmacology. Drug treatments Predictive Value of Tests Prospective Studies Rats Rats, Sprague-Dawley Stroke - complications Stroke - drug therapy Stroke - enzymology Tissue Plasminogen Activator - adverse effects Treatment Outcome Vascular diseases and vascular malformations of the nervous system |
| title | Plasma VAP-1/SSAO Activity Predicts Intracranial Hemorrhages and Adverse Neurological Outcome After Tissue Plasminogen Activator Treatment in Stroke |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T21%3A19%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20VAP-1/SSAO%20Activity%20Predicts%20Intracranial%20Hemorrhages%20and%20Adverse%20Neurological%20Outcome%20After%20Tissue%20Plasminogen%20Activator%20Treatment%20in%20Stroke&rft.jtitle=Stroke%20(1970)&rft.au=HERNANDEZ-GUILLAMON,%20Mar&rft.date=2010-07-01&rft.volume=41&rft.issue=7&rft.spage=1528&rft.epage=1535&rft.pages=1528-1535&rft.issn=0039-2499&rft.eissn=1524-4628&rft.coden=SJCCA7&rft_id=info:doi/10.1161/STROKEAHA.110.584623&rft_dat=%3Cproquest_cross%3E733477753%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733477753&rft_id=info:pmid/20538694&rfr_iscdi=true |